Eli Lilly and Company, a global pharmaceutical giant, remains a cornerstone of innovation in Indianapolis, Indiana. The Eli Lilly and Company address at Lilly Corporate Center, 893 South Delaware Street, Indianapolis, IN 46285, serves as the headquarters for a company driving advancements in diabetes, oncology, and neuroscience. Recent developments highlight Lilly’s commitment to expanding its presence, both physically and in the digital realm, while continuing to shape the future of healthcare. This article explores the latest news surrounding the Eli Lilly and Company address, from corporate expansions to community impact, based on the most current information available as of June 2025.
Headquarters at the Heart of Innovation
The Eli Lilly and Company address in Indianapolis is more than just a location—it’s a hub for groundbreaking research and development. The Lilly Corporate Center houses state-of-the-art facilities where scientists work on life-changing medications like Mounjaro and Zepbound. In May 2025, Lilly announced a $27 billion investment to build four new U.S. manufacturing sites, with significant upgrades planned for its Indianapolis headquarters. This expansion aims to boost production capacity for diabetes and obesity drugs, addressing global demand. The Indianapolis site remains central to Lilly’s operations, employing thousands and fostering a culture of scientific discovery.
Beyond manufacturing, the headquarters hosts Lilly’s mobile research units, which gained prominence during the COVID-19 pandemic. These units, initially deployed to nursing homes, now support clinical trials for Alzheimer’s and other diseases, bringing research directly to communities. The Eli Lilly and Company address symbolizes a legacy of innovation, dating back to 1876 when Colonel Eli Lilly founded the company with a vision to improve lives through science.
Recent Developments at the Indianapolis Hub
Lilly’s Indianapolis headquarters continues to make headlines. In June 2025, the company announced a $1.3 billion acquisition of Verve Therapeutics, a Boston-based gene-editing firm focused on cardiovascular treatments. While the deal itself is centered in Boston, the strategic planning and integration efforts are being orchestrated from the Eli Lilly and Company address in Indianapolis. This acquisition underscores Lilly’s push into genetic medicine, with the headquarters serving as the nerve center for these high-stakes partnerships.
Additionally, Lilly has enhanced its digital presence through LillyDirect, a platform launched to improve access to medications like Zepbound. As of June 2025, LillyDirect now offers higher-dose versions of the weight-loss drug directly to consumers, a move coordinated from the Indianapolis headquarters. This initiative reflects Lilly’s focus on accessibility, ensuring patients can connect with its medicines seamlessly, no matter where they are.
Community Impact and Global Reach
The Eli Lilly and Company address in Indianapolis isn’t just about corporate operations—it’s a vital part of the local community. Lilly’s philanthropy, rooted in its founding values, continues to thrive. In 2025, the company expanded its Lilly Cares Foundation, providing free medications to qualifying U.S. patients with financial need. This program, managed from the Indianapolis headquarters, has helped thousands access critical treatments for diabetes and cancer.
Globally, Lilly’s influence extends far beyond its Indiana base. With offices in 18 countries and products sold in 125, the company’s Indianapolis hub oversees strategic partnerships, such as a recent collaboration with Rznomics for RNA-based gene therapies. These efforts, driven from the Eli Lilly and Company address, highlight Lilly’s role as a global healthcare leader committed to addressing unmet medical needs.
Key Developments at a Glance
| Development | Details | Impact |
|---|---|---|
| Manufacturing Expansion | $27 billion investment in four new U.S. sites, including upgrades in Indianapolis | Increases production capacity for diabetes and obesity drugs |
| Verve Therapeutics Acquisition | $1.3 billion deal for gene-editing expertise | Strengthens Lilly’s cardiovascular treatment pipeline |
| LillyDirect Platform | Higher-dose Zepbound now available online | Improves patient access to weight-loss medications |
| Lilly Cares Foundation | Expanded free medication program | Supports underserved communities in the U.S. |
Looking Ahead: Lilly’s Vision from Indianapolis
As Lilly continues to grow, the Eli Lilly and Company address remains the heartbeat of its operations. The Indianapolis headquarters is not only a physical location but also a symbol of the company’s enduring mission to make life better through science. With ongoing investments in manufacturing, cutting-edge partnerships, and patient-focused initiatives like LillyDirect, Lilly is poised to lead the pharmaceutical industry for years to come. The company’s focus on accessibility and innovation ensures that its Indianapolis base will continue to drive global impact.
For those interested in Lilly’s work, visiting the headquarters or exploring career opportunities can offer a closer look at this dynamic organization. The company’s commitment to community engagement and scientific advancement makes it a beacon of progress in Indianapolis and beyond.
Stay Connected with Eli Lilly
Want to learn more about Eli Lilly’s groundbreaking work or explore opportunities at its Indianapolis headquarters? Visit lilly.com for the latest updates, career openings, or to connect with the Lilly Cares Foundation for patient support.